Aneurysmal Subarachnoid Hemorrhage Drugs Market Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc.

Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 20172023," the global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023.

Access full summary at: https://www.alliedmarketresearch.com/aneurysmal-subarachnoid-hemorrhage-drugs-market

Aneurysmal subarachnoid hemorrhage is a kind of stroke, which is caused by bleeding in the subarachnoid space of the brain. The major reasons for aneurysmal subarachnoid hemorrhage include brain aneurysm, arteriovenous malformation, or head injury. Change in lifestyles such as smoking and alcohol consumption increase the risk for aSAH, as well as rise in geriatric population are the major factors that contribute to the growth of the market. Moreover, increase in prevalence of hypertension, and stroke further boost the market growth. However, the associated side effects of the drugs are expected to impede the market growth. In addition, a need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage provide lucrative opportunities for the market growth.

Opioid analgesics generated the maximum revenue, accounting for more than two-fifths share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016. The calcium channel blockers segment is expected to witness the highest CAGR of 4.5% during the forecast period, owing to their ability to reduce the risk of brain damage.

Get PDF Sample for Details market study: https://www.alliedmarketresearch.com/request-sample/4602

Key Findings of the Aneurysmal Subarachnoid Hemorrhage Drugs Market:
The opioid analgesics segment is expected to grow at a significant CAGR of 2.6% during the forecast period.

The anticonvulsants segment contributed nearly one-fourth share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016.
The stool softeners segment is projected to grow at a significant CAGR of 4.2% during the forecast period.

Germany and France are the major shareholders, which collectively accounted for more than one-third share of the European aneurysmal subarachnoid hemorrhage drugs market in 2016.

Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific aneurysmal subarachnoid hemorrhage drugs market in 2016.
The Asia-Pacific market is projected to grow at the highest CAGR of 5.5% during the forecast period, owing to rise in awareness about the treatment of aneurysmal subarachnoid hemorrhage in the healthcare industry and surge in expenditures in emerging markets (such as India and China) to cater to the unmet medical needs.

Significant Note: Customize Report As per your Requirements: https://www.alliedmarketresearch.com/request-for-customization/4602

The major companies profiled in the report are
• Arbor Pharmaceuticals Inc.
• Edge Therapeutics Inc.
• Johnson & Johnson (Actelion Pharmaceuticals Ltd.)
• Mylan N.V.
• Orexo AB
• Pfizer Inc.
• Purdue Pharma L.P.
• Pharmaxis Ltd.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.